Výsledky vyhledávání - "Marco Pagliuchi"

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients

Autor: Cirino Botta, Assunta Basile, Maria Grazia Cusi, Pierosandro Tagliaferri, Pierpaolo Correale, Giacomo Maria Guidelli, Veronica Ricci, Elodia Claudia Martino, Salvatore Francesco Carbone, Marco Pagliuchi, Pierpaolo Pastina, Claudia Gandolfo, Antonella Fioravanti, Luigi Pirtoli, Pierfrancesco Tassone, Lucia Micheli, Elena Dreassi, Maria Grazia Rossetti

Publikováno v: Cancer immunology, immunotherapy : CII. 64(9)

Thymidylate synthase (TS) poly-epitope peptide (TSPP) is a 27-mer peptide vaccine containing the amino acidic sequences of three epitopes with HLA-A2.1-binding motifs of TS, an enzyme overexpressed in cancer cells, which plays a crucial role in DNA r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f336856f1993d73d0413d3bf3a9b2f1
https://pubmed.ncbi.nlm.nih.gov/26031574

Zobrazit plný text záznamu

Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients

Autor: Michele Caraglia, Serena Apollinari, Ornella Romano, Marco Pagliuchi, Cirino Botta, Ignazio Martellucci, Raffaele Addeo, Luca Luzzi, Gabriella Misso, Pierpaolo Correale, Giuseppe Gotti, Elena Bestoso, Pierosandro Tagliaferri, Maria Saveria Rotundo, Assunta Basile, Monica Lamberti, Antonella Licchetta, Alberto Abbruzzese

Publikováno v: Cancer biologytherapy. 12(2)

Bevacizumab, is a humanized monoclonal antibody to vasculo-endothelial- growth-factor, with anticancer activity in non-small-cell-lung cancer (NSCLC) patients. Our previous results from a dose/finding phase I trial in NSCLC patients, demonstrated the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::553e9423b07e54436c810771a2f391f2
https://pubmed.ncbi.nlm.nih.gov/21525780

Zobrazit plný text záznamu

Phase Ib study of TSPP (thymidilate synthase poly-epitope peptide) vaccine in combination with GOLFIG chemoimmuno-burst in advanced colon cancer patients: Results from the TSPP/VAC-1/c trial

Autor: Pierosandro Tagliaferri, Serena Apollinari, Marco Pagliuchi, Assunta Basile, Pierpaolo Pastina, Veronica Ricci, Federico Chellini, Antonella Fioravanti, Luigi Pirtoli, Elena Bestoso, Maria Grazia Cusi, Salvatore Carbone, Gianni Gori Savellini, Maria Grazia Rossetti, Giacomo Maria Guidelli, Pierpaolo Correale, Cirino Botta, Giovanni Mantovani

Publikováno v: Journal of Clinical Oncology. 30:e13098-e13098

e13098 Background: TSPP is a poly-epitope peptide anticancer vaccine able to generate a thymidylate syntase (TS) specific T cell response with antitumor activity in preclinical models, expecially when used in sequential combination with 5-FU. TS is i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f063603dff7e1f3cd70c6456bfcf750c
https://doi.org/10.1200/jco.2012.30.15_suppl.e13098

Zobrazit plný text záznamu

Abstract LB-229: Treatment of advanced cancer patients with a newest poly-epitope peptide vaccine to the thymidylate synthase(TSPP): a phase Ib (TSPP/VAC1) trial

Autor: Federico Chellini, Pierpaolo Pastina, Giacomo Maria Guidelli, Pierosandro Tagliaferri, Maria Grazia Cusi, Marco Pagliuchi, Cirino Botta, Pierpaolo Correale, Gianni Gori Savellini, Elena Bestoso, Maria Grazia Rossetti, Maria Assunta Basile, Antonella Fioravanti, Luigi Pirtoli, Serena Apollinari

Publikováno v: Cancer Research. 72:LB-229

Background TSPP is a poly-epitope peptide vaccine to the thymidylate syntase (TS) an enzyme commonly over-expressed in replicating cancer cells and recognized as a major target of fluoropyrimidines. TSPP showed immunological and anticancer activity i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9883b74f6b955983d7d449b6774625db
https://doi.org/10.1158/1538-7445.am2012-lb-229

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání